Unnamed: 0,title,date,stock,sentiment
629140.0,Heron Therpeutics Highlights Publication Of Results From Phase 2b Study Of HTX-011 In Patients Undergoing Total Knee Arthroplasty,2020-06-04 09:14:00-04:00,HRTX,neutral
629141.0,"Guggenheim Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $24",2020-05-27 06:09:00-04:00,HRTX,neutral
629142.0,Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain,2020-05-18 09:02:00-04:00,HRTX,negative
629143.0,"Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $44",2020-03-02 12:36:00-05:00,HRTX,negative
629144.0,"Heron Therapeutics Q4 EPS $(0.65) Down From $(0.63) YoY, Sales $35.083M Up From $28.844M YoY",2020-03-02 07:33:00-05:00,HRTX,neutral
629145.0,"Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $48",2020-02-20 06:04:00-05:00,HRTX,negative
629146.0,Heron Therapeutics shares are trading lower after the company announced the FDA extended the review period for the NDA for HTX-011.,2020-02-19 16:38:00-05:00,HRTX,neutral
629147.0,Heron Therapeutics Announces FDA Extension of Review Period For NDA For HTX-011,2020-02-19 16:20:00-05:00,HRTX,neutral
629148.0,Heron Therapeutics shares are trading higher. Not currently seeing any company-specific news.,2020-01-22 11:52:00-05:00,HRTX,positive
629149.0,Heron Therapeutics Highlights Progress In Pain Management And CINV Franchises,2020-01-13 08:37:00-05:00,HRTX,negative
629150.0,"Heron Therapeutics Highlights Publication Of Mechanism Of Action Data For HTX-011, A Dual-Acting Local Anesthetic Being Developed For Management of Postoperative Pain",2019-12-16 16:10:00-05:00,HRTX,negative
629151.0,Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain,2019-12-03 07:37:00-05:00,HRTX,negative
629152.0,"Heron Therapeutics Q3 EPS $(0.42) Up From $(0.49) YoY, Sales $42.6M Up From $19.786M YoY",2019-11-12 08:36:00-05:00,HRTX,neutral
629153.0,Heron Therapeutics Announces FDA Acceptance Of New Drug Application Resubmission For HTX-011 For Management Of Postoperative Pain,2019-10-28 08:30:00-04:00,HRTX,negative
629154.0,Heron Announces FDA Approval of Supplemental New Drug Application To Expand CINVANTI Label For Single-Dose Regimen For Patients Receiving Moderately Emetogenic Chemotherapy,2019-10-22 08:34:00-04:00,HRTX,positive
629155.0,Heron Therapeutics Late Thursday Priced 8.571M Shares At $17.50/Share,2019-10-04 10:21:00-04:00,HRTX,positive
629156.0,Heron Therapeutics shares are trading lower after the company announced a common stock offering with no size disclosed.,2019-10-04 08:10:00-04:00,HRTX,negative
629157.0,Heron Therapeutics shares are trading lower after the company announced a common stock offering with no size disclosed.,2019-10-03 16:05:00-04:00,HRTX,negative
629158.0,"Heron Therapeutics Reports Offering Of Common Stock, No Size Disclosed",2019-10-03 16:01:00-04:00,HRTX,negative
629159.0,"JMP Securities Reiterates Market Outperform on Heron Therapeutics, Lowers Price Target to $32",2019-10-03 07:36:00-04:00,HRTX,positive
629160.0,Heron Announces Topline Results From Phase 3b Clinical Study Of HTX-011 In Total Knee Arthroplasty,2019-10-02 07:46:00-04:00,HRTX,neutral
629161.0,Heron Therapeutics Resubmits New Drug Application To FDA For HTX-011 For The Management Of Postoperative Pain,2019-10-01 08:31:00-04:00,HRTX,negative
629162.0,Heron Therapeutics Highlights Publication Of Results From EPOCH 2 Phase 3 Study Of HTX-011 In Patients Undergoing Hernia Repair Surgery,2019-08-20 08:38:00-04:00,HRTX,neutral
629163.0,"Heron Therapeutics Q2 EPS $(0.63) Down From $(0.54) YoY, Sales $36.7M Up From $17.277M YoY",2019-08-05 08:35:00-04:00,HRTX,neutral
629164.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,HRTX,negative
629165.0,Heron Therapeutics Shares Up 1% To Session High; Hearing Cowen Said Form 483S Filed With FDA Indicates CMC Issues Are Resolvable,2019-06-28 09:38:00-04:00,HRTX,positive
629166.0,Heron Therapeutics Highlights Publication Of Results From Phase 3 EPOCH 1 Study Of HTX-011 In Patients Undergoing Bunionectomy,2019-05-21 09:15:00-04:00,HRTX,neutral
629167.0,Heron Therapeutics Reports Presentation Of New Results From Study Showing 95% of Postoperative Patients Remain Opioid-Free when HTX-011 Is Given with an Over-the-Counter Analgesic Regimen,2019-05-14 08:32:00-04:00,HRTX,neutral
629168.0,"Heron Therapeutics Q1 EPS $(0.8) Misses $(0.49) Estimate, Sales $31.6M Beat $28.04M Estimate",2019-05-09 08:36:00-04:00,HRTX,negative
629169.0,Heron Therapeutics Reports Partnership with National Academy Of Medicine's Action Collaborative On Countering US Opioid Epidemic,2019-05-07 16:40:00-04:00,HRTX,neutral
629170.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Thurs., May 1, 2019",2019-05-02 10:01:00-04:00,HRTX,positive
629171.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., May 1, 2019",2019-05-01 10:22:00-04:00,HRTX,positive
629172.0,Heron Therapeutics shares are trading lower after the FDA rejected the company's marketing application for a pain treatment.,2019-05-01 09:17:00-04:00,HRTX,negative
629173.0,Heron Therapeutics is trading lower after the company reported it received a Complete Response Letter from the FDA for its post-operative pain drug candidate.,2019-05-01 09:00:00-04:00,HRTX,negative
629174.0,"Heron Therapeutics Shares Resume Trade, Down 31.5%",2019-05-01 08:30:00-04:00,HRTX,positive
629175.0,Pacira Biosciences Shares Spike ~12% Premarket Following Complete Response Letter From Heron Therapeutics For Its Postoperative Pain Treatment; BZ NOTE: Pacira Has A Competing Drug Candidate,2019-05-01 08:08:00-04:00,HRTX,neutral
629176.0,UPDATE: Heron Says Plans To Request FDA Meeting To Obtain Deal On Co.'s Approach To Resolve Issues Outlined By FDA's CRL,2019-05-01 08:05:00-04:00,HRTX,positive
629177.0,"UPDATE: Heron Says 'No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data'",2019-05-01 08:05:00-04:00,HRTX,negative
629178.0,Heron Therapeutics Shares To Resume Trade At 8:30 a.m. EDT,2019-05-01 08:04:00-04:00,HRTX,positive
629179.0,Heron Therapeutics Reports Received Complete Response Letter For HTX-011,2019-05-01 08:00:00-04:00,HRTX,neutral
629180.0,Heron Therapeutics Shares Halted News Pending,2019-05-01 07:57:00-04:00,HRTX,positive
629181.0,Heron Therapeutics Announces its Marketing Authorization Application for HTX-011 Was Approved by the European Medicines Agency,2019-04-01 08:36:00-04:00,HRTX,positive
629182.0,Heron Therapeutics Gives an Update on HTX-011,2019-03-11 08:33:00-04:00,HRTX,neutral
629183.0,Heron Therapeutics Reports FDA Approval Of Supplemental New Drug Application To Expand CINVANTI Label For IV Push,2019-02-26 16:43:00-05:00,HRTX,positive
629184.0,"Heron Therapeutics Q4 EPS $(0.63) Misses $(0.46) Estimate, Sales $28.8M Beat $26.93M Estimate",2019-02-22 08:32:00-05:00,HRTX,negative
629185.0,Heron Therapeutics Reports Pres Robert Rosen To Retire; CEO Barry Quart Will Take On Added Role Of Pres,2019-02-05 16:34:00-05:00,HRTX,neutral
629186.0,"Heron Therapeutics Announces a PDUFA Date of April 30th, 2019 For HTX-011",2019-01-07 08:41:00-05:00,HRTX,neutral
629187.0,Heron Therapeutics Sees FY2018 Sales $76.70M vs $72.41M Est,2019-01-07 08:40:00-05:00,HRTX,neutral
629188.0,Heron Therapeutics Sees Q4 Sales $28.10M vs $23.72M Est,2019-01-07 08:39:00-05:00,HRTX,neutral
629189.0,Heron Therapeutics Announces Study Results Showing 90% Of Patients Remained Opioid-Free When Its HTX-011 Was Given With An Over-the-Counter Analgesic Regimen,2019-01-03 08:38:00-05:00,HRTX,neutral
629190.0,Heron Therapeutics shares are trading higher after the FDA granted priority review designation for its new drug application for HTX-011.,2018-12-31 09:38:00-05:00,HRTX,positive
629191.0,Heron Therapeutics Reports FDA Granted Priority Review Designation For Its New Drug Application For HTX-011,2018-12-31 08:31:00-05:00,HRTX,positive
629192.0,"Heron Therapeutics Q3 EPS $(0.49) Misses $(0.45) Estimate, Sales $19.786M Beat $19.09M Estimate",2018-11-07 17:06:00-05:00,HRTX,negative
629193.0,Heron Submits a New Drug Application to the FDA for HTX-011,2018-10-31 16:04:00-04:00,HRTX,neutral
629194.0,"Stifel Nicolaus Initiates Coverage On Heron Therapeutics with Buy Rating, Announces $55 Price Target",2018-09-14 07:06:00-04:00,HRTX,neutral
629195.0,Heron Therapeutics Q2 EPS $(0.54) Beats $(0.70) Estimate,2018-08-08 08:37:00-04:00,HRTX,neutral
629196.0,"Cantor Fitzgerald Maintains Overweight on Heron Therapeutics, Raises Price Target to $50",2018-07-19 08:10:00-04:00,HRTX,negative
629197.0,Heron Therapeutics Prices $200M Public Offering of Common Stock; Price Not Disclosed,2018-06-26 04:06:00-04:00,HRTX,neutral
629198.0,Heron Therapeutics Announces $200M Common Stock Offering,2018-06-25 16:02:00-04:00,HRTX,neutral
629199.0,"Oppenheimer Maintains Outperform on Heron Therapeutics, Raises Price Target to $50",2018-06-22 07:42:00-04:00,HRTX,neutral
629200.0,Heron Therapeutics Option Alert: Jul 20 $33 Puts Sweep (2) near the Bid: 1143 @ $0.401 vs 2955 OI; Earnings 8/8 After Close [est] Ref=$40.05,2018-06-21 11:04:00-04:00,HRTX,positive
629201.0,Evercore Raises Heron Therapeutics Price Target From $56 To $80 And Remains A Top Pick Following '011 P2b Data That Was 'Rock Solid',2018-06-21 10:28:00-04:00,HRTX,positive
629202.0,"Shares of Heron Therapeutics Up 27.8%, Traders Circulating Chatter That Evercore Increased Co.'s Price Target To $80",2018-06-21 10:25:00-04:00,HRTX,positive
629203.0,Heron Therapeutics Reports HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDA Conference Call and Webcast Today at 8:30 a.m. ET,2018-06-21 08:05:00-04:00,HRTX,negative
629204.0,"Jefferies Global Healthcare Begins Today, Presenters Include: Kadmon, Aeri Pharma, Chemed, Orthofix, Revance, Heron Therapeutics, and Dicerna Pharma",2018-06-05 08:55:00-04:00,HRTX,neutral
629205.0,"Heron Therapeutics Q1 EPS $(0.81) Beats $(0.86) Estimate, Sales $11.6M Beat $11.24M Estimate",2018-05-10 08:41:00-04:00,HRTX,neutral
629206.0,"Evercore Out Positive On Heron Therapeutics, Gives Bullish Scenario Of $150/Share If HTX-011 Is Rapidly Adopted By Hospital Pharmacies & Committees, Is Able To Expand Into Low Vol. Procedures, And Is Able To Reduce Hospitalization Duration Post-Procedures",2018-04-05 10:28:00-04:00,HRTX,positive
629207.0,"Heron Therapeutics Announces Common Stock Offering, No Size Disclosed",2018-03-28 16:15:00-04:00,HRTX,negative
629208.0,"Benzinga Pro's Most-Searched Tickers For Tues., Mar. 20",2018-03-20 14:49:00-04:00,HRTX,neutral
629209.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Mon., Mar. 19",2018-03-19 17:25:00-04:00,HRTX,positive
629210.0,"Heron Therapeutics Shares Up 24.9% On News Phase 3 Trial Of HTX-011 Met All Primary, Key Secondary Endpoints",2018-03-19 11:27:00-04:00,HRTX,positive
629211.0,Heron Therapeutics' Phase 3 Trial of HTX-011 Met all Primary and Key Secondary Endpoints,2018-03-19 08:03:00-04:00,HRTX,neutral
629212.0,"Heron Therapeutics Reports Q4 EPS $(1.09) vs $(0.79) Est., Net Product Sales Of SUSTOL $10.1M vs $9.3M Est.",2018-02-27 17:18:00-05:00,HRTX,neutral
629213.0,"Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma",2018-02-14 07:06:00-05:00,HRTX,neutral
629214.0,"Heron Therapeutics Earlier Reported Prelim. Q4 SUSTOL Sales $10M, FY17 SUSTOL Sales $31M Above Guidance OF $25M-$30M; Sees FY18 CINV Net Sales $60M-$70M",2018-01-08 12:49:00-05:00,HRTX,neutral
629215.0,"Leerink Swann Initiates Coverage On Heron Therapeutics with Outperform Rating, Announces $22.00 Price Target",2018-01-03 08:37:00-05:00,HRTX,neutral
629216.0,"Heron Therapeutics Reports Public Offering of Common Stock, Terms Not Disclosed",2017-12-04 16:03:00-05:00,HRTX,neutral
629217.0,"Jefferies 2017 London Healthcare Conference Concludes Today, Presenters Include: Ignyta, Heron Therapeutics, and TherapeuticsMD",2017-11-16 09:28:00-05:00,HRTX,neutral
629218.0,"Heron Therapeutics Shares, Previously Halted, Have Resumed, Now Down 0.29% After Hours",2017-11-09 16:30:00-05:00,HRTX,positive
629219.0,Heron Therapeutics Announces U.S. FDA Approval of CINVANTI,2017-11-09 16:10:00-05:00,HRTX,positive
629220.0,"Heron Therapeutics Reports Q3 EPS $(0.77) vs $(0.86) Est., Sales $8.572M vs $8.22M Est.",2017-11-06 08:34:00-05:00,HRTX,neutral
629221.0,"Oppenheimer Initiates Coverage On Heron Therapeutics with Outperform Rating, Announces $27.00 Price Target",2017-10-31 08:14:00-04:00,HRTX,neutral
629222.0,Northland Securities Initiates Coverage On Heron Therapeutics with Outperform Rating,2017-09-27 10:03:00-04:00,HRTX,positive
629223.0,"Mizuho Initiates Coverage On Heron Therapeutics with Buy Rating, Announces $28.00 Price Target",2017-09-27 06:15:00-04:00,HRTX,neutral
629224.0,"Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma",2017-09-25 09:30:00-04:00,HRTX,neutral
629225.0,Heron Therapeutics Initiates Phase 3 Program For HTX-011 After Successful FDA Meeting,2017-08-09 17:08:00-04:00,HRTX,positive
629226.0,"Heron Therapeutics Reports Q2 EPS $(0.80) vs $(0.92) Est., Sales $8.5M vs $5.5M Est.",2017-08-09 16:22:00-04:00,HRTX,neutral
629227.0,"Heron Therapeutics Fils For Potential Mixed Shelf, No Size Disclosed",2017-07-06 16:21:00-04:00,HRTX,negative
629228.0,"Jefferies Health Care Conference Begins Today, Presenters Include: Agilent Technologies, Civitas Solutions, Aeri Pharmaceuticals, Alkermes, Alnylam Pharmaceuticals, Heron Therapeutics",2017-06-06 08:47:00-04:00,HRTX,positive
629229.0,"Heron Therapeutics Reports Q1 EPS $(1.00) vs $(0.91) Est., Net Product Sales of SUSTOL $3.6M vs $2.6M Est.",2017-05-10 08:08:00-04:00,HRTX,neutral
629230.0,Heron Therapeutics Names Robert E. Hoffman as CFO,2017-04-24 16:09:00-04:00,HRTX,neutral
629231.0,"Needham Initiates Coverage On Heron Therapeutics With Buy, Announces $28 Price Target",2017-02-27 09:05:00-05:00,HRTX,neutral
629232.0,"Heron Therapeutics Reports Q4 EPS $(1.22) vs $(1.17) Est., Sales $1.279B vs $1.09B Est.",2017-02-23 16:41:00-05:00,HRTX,neutral
629233.0,Heron Therapeutics FIles 12.3M Share Offering at $12.20/Share,2017-01-19 06:28:00-05:00,HRTX,positive
629234.0,Filing from Heron Therapeutics Shows Registration for $150M Common Stock Offering,2017-01-18 16:04:00-05:00,HRTX,neutral
629235.0,Heron Announces Submission of CINVANTI NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting,2017-01-12 08:31:00-05:00,HRTX,neutral
629236.0,"Adam Feuerstein Tweets: $HRTX forecasts Sustol net sales of $15-25M in 2017. Current consensus is $46.5M, per FactSet.",2017-01-04 16:34:00-05:00,HRTX,neutral
629237.0,Heron Therapeutics Reports Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies,2017-01-04 16:12:00-05:00,HRTX,negative
629238.0,"Aegis Capital Initiates Coverage On Heron Therapeutics, Inc. - Common Stock at Buy, Announces $41.00",2016-10-26 09:22:00-04:00,HRTX,neutral
629239.0,"Brean Capital Assumes Heron Therapeutics at Buy, Announces $41.00 PT",2016-10-04 05:57:00-04:00,HRTX,neutral
629240.0,"Lake Street Assumes Heron Therapeutics at Buy, Announces $45.00 PT",2016-09-06 08:04:00-04:00,HRTX,neutral
629241.0,"Cantor Fitzgerald Initiates Coverage on Heron Therapeutics at Buy, Announces $41.00 PT",2016-05-02 16:44:00-04:00,HRTX,neutral
629242.0,"Lake Street Capital Initiated Coverage on Heron Therapeutics at Buy, Announced $45.00 PT Before the Open",2015-12-10 09:44:00-05:00,HRTX,neutral
629243.0,Heron Therapeutics to Present Data From Completed Phase 3 MAGIC Study of SUSTOL at ASCO,2015-09-22 08:05:00-04:00,HRTX,neutral
629244.0,"Bank of America Initiates Coverage on Heron Therapeutics at Buy, Announces $46.00 PT",2015-09-02 08:57:00-04:00,HRTX,neutral
629245.0,"Cowen & Company Initiates Coverage on Heron Therapeutics at Outperform, Announces $40.00 PT",2015-06-26 06:34:00-04:00,HRTX,neutral
629246.0,Jefferies Initiates Coverage on Heron Therapeutics at Buy,2015-03-20 04:48:00-04:00,HRTX,neutral
629247.0,Heron Therapeutics Announces Positive Results From Phase 1 Study of HTX-011,2015-03-19 08:11:00-04:00,HRTX,positive
629248.0,"Noble Financial Initiates Coverage on Heron Therapeutics Inc at Buy, Announces $18.00 PT",2014-08-07 06:23:00-04:00,HRTX,positive
629249.0,Heron Therapeutics Inc Reports Q2 EPS of $(0.78) vs $(0.74) Est,2014-08-04 08:05:00-04:00,HRTX,neutral
629250.0,Morning Market Losers ,2014-06-25 09:49:00-04:00,HRTX,negative
629251.0,Heron Therapeutics Prices 4.5M Share Offering at $11.74/Share,2014-06-25 09:15:00-04:00,HRTX,positive
629252.0,Heron Therapeutics Announces Proposed Secondary,2014-06-24 16:02:00-04:00,HRTX,neutral
629253.0,8-K from Heron Therapeutics Shows COO Davis Will Step Down,2014-06-19 17:35:00-04:00,HRTX,neutral
629254.0,"Heron Therapeutics Offers Update on SUSTOL Program, Says Now Plans to Include Delayed-HEC in NDA Resubmission",2014-06-02 07:59:00-04:00,HRTX,neutral
629255.0,Heron Therapeutics Announces Positive Results for HTX-011,2014-05-14 08:16:00-04:00,HRTX,positive
629256.0,Heron Therapeutics Files $100M Mixed Securities Shelf,2014-05-13 17:23:00-04:00,HRTX,positive
629257.0,Heron Therapeutics Initiates Phase 3 Label Expansion Study of SUSTOL,2014-03-31 08:03:00-04:00,HRTX,neutral
